Recently, a new compound targeting calcium release-activated calcium (CRAC) channels including Orai1 and Orai3 channels has been developed by Rhizen pharmaceuticals for the treatment of the non-small cell lung cancer (Patent US 2011/0112058 A1, [38]). This evidence concerns the gene ORAI1 and non-small cell lung carcinoma.